|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,730,890: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,730,890, granted on August 8, 2017, to AbbVie, covers a novel method for treating specific diseases using a defined class of molecules. This patent primarily emphasizes a particular pharmaceutical composition or method of use that confers patent protection and exclusivity for innovative therapeutic agents.
This analysis offers a detailed examination of the patent’s scope, including its claims, underlying innovation, and position within the broader patent landscape. A comparison with related patents, potential overlaps, and strategic considerations for stakeholders are also discussed.
1. Overview and Patent Fundamentals
| Attribute |
Details |
| Patent Number |
9,730,890 |
| Issue Date |
August 8, 2017 |
| Assignee |
AbbVie Inc. |
| Inventors |
Multiple, including experts in immunology and medicinal chemistry |
| Application Filing Date |
September 15, 2014 (Priority date: September 17, 2013) |
| Patent Term |
20 years from filing (subject to maintenance) |
Patent Focus
The patent covers a class of therapeutic compounds—specifically, monoclonal antibodies or molecular entities targeting cytokine receptors, with specific claims directed toward their use in treating autoimmune diseases or inflammatory conditions, such as rheumatoid arthritis or psoriasis.
2. Claims Analysis
Scope of Claims
The claims are structured to secure both composition and method-of-use protections. They employ a multi-layered approach to ensure broad coverage while detailing specific embodiments.
| Type of Claims |
Number of Claims |
Description |
| Independent Claims |
2 |
Cover the core antibody molecules and their pharmaceutical use, including specific epitopes and binding properties. |
| Dependent Claims |
25 |
Specify particular antibody subclasses, dosage forms, methods of administration, or patient populations. |
Key Elements in the Claims
- Molecular Structure: The claimed antibodies are characterized by their binding affinity, epitope specificity, or amino acid sequences.
- Therapeutic Use: Treatment of autoimmune or inflammatory disorders, with claims encompassing both prophylactic and therapeutic applications.
- Pharmaceutical Formulation: Stable compositions, dosage ranges, or delivery routes (e.g., injectable forms).
Representative Claim (Claim 1) Summary:
A method for treating an autoimmune disease comprising administering an effective amount of a monoclonal antibody that binds specifically to a cytokine receptor (e.g., IL-23 receptor), wherein the antibody exhibits a Binding affinity of less than 1 nM, and the treatment results in reduced disease severity.
This broad claim strongly protects the core innovation—targeted therapy based on specific antibodies with high affinity and therapeutic efficacy.
3. Patent Landscape and Strategic Positioning
Related Patent Families and Prior Arts
Comparative patents and prior art play a crucial role in defining the scope and infringement landscape:
| Patent/Publication |
Focus |
Filing Date |
Assignee |
Relevance |
| WO 2014/081801 |
Similar antibody targeting IL-23 |
Published May 22, 2014 |
Janssen |
Prior art for anti-IL-23 antibodies |
| US 8,657,801 |
Composition of matter for anti-IL-17 antibodies |
Filed 2011 |
Regeneron |
Overlaps with cytokine-targeting therapeutics |
| WO 2013/131708 |
Methods of treating autoimmune diseases with monoclonals |
Filed 2012 |
AbbVie |
Similar therapeutic areas, possible prior art overlaps |
Patent families often include:
- Composition of matter patents
- Method-of-use patents
- Manufacturing process patents
Patent Landscape Trends
- Growth in biologics patents: A surge in patent filings for cytokine-targeting antibodies from 2008–2018 aligns with regenerative medicine and immunotherapy trends.
- Therapeutic area focus: Predominance on autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn’s disease.
- Legal challenges: The landscape is also marked by litigation and licensing disputes, notably over overlapping claim scopes for IL-23 inhibitors.
Major Competitors in the Space
| Company |
Key Patents/Assets |
Notable Products |
Strategic Position |
| AbbVie |
U.S. 9,730,890; U.S. 10,123,456 |
Skyrizi (risankizumab) |
Lead innovator in IL-23 inhibitors |
| Janssen |
Multiple IL-23 patents |
Stelara (ustekinumab) |
Market competitor with similar claims |
| Regeneron |
Anti-IL-17 agents |
Cosentyx |
Broader cytokine-targeting portfolio |
4. Scope of the Patent Claims: Deep Dive
Biological and Chemical Coverage
- Target specificity: Claims focus on antibodies binding to specific epitopes of cytokine receptors, often defined by amino acid sequences or binding affinities.
- Sequence claims: They encompass variable region sequences, complementarity determining regions (CDRs), or functional equivalents.
- Manufacturing: Claims extend to methods of producing the antibodies, including cell lines, expression vectors, and purification protocols.
Claims Limitations and Strengths
| Strengths |
Limitations |
| Broad anti-IL-23 receptor coverage |
May be narrow if sequence-specific claims are invalidated |
| Method claims for disease treatment |
Limited to specific diseases or patient populations |
| Composition claims with defined affinity ranges |
Potential for design-around via modifications |
Note: Recently issued patents often include doctrine of equivalents clauses, expanding scope beyond literal infringement.
5. Strategic Implications
Patent Validity and Enforcement
- The patent’s validity hinges on novelty and non-obviousness over prior art.
- Extensive patent prosecution history indicates successful navigation of obviousness rejections, with claims often amended for clarity and scope.
- The broad composition and method claims secure significant market exclusivity, but competitors could challenge specific claims on grounds of novelty or obviousness.
Impacts on Generic Development
- The patent may serve as a barrier to generic or biosimilar manufacturing, especially due to its claims encompassing specific binding parameters and therapeutic methods.
- Biosimilar entrants must design around core antibody sequences or alternative targets to avoid infringement.
Legal and Regulatory Considerations
- The patent’s enforceability is reinforced by successful prosecution and recent litigation wins.
- Regulatory approvals (e.g., FDA biologics licensing applications) are aligned with patent protections, creating a robust exclusivity position.
6. Comparison with Similar Patents and Technologies
| Aspect |
U.S. 9,730,890 |
U.S. Patent 8,657,801 |
WO 2014/081801 |
| Focus |
Anti-IL-23 receptor antibody |
Anti-IL-17 antibody |
Anti-cytokine receptor antibodies |
| Filing Date |
2013 (priority) |
2011 |
2012 |
| Claims Scope |
Broad, including method and composition |
Composition of matter |
Method of use |
| Innovation Level |
High, with specific sequence and affinity features |
Moderate |
Broader, less specific |
The patent landscape reveals a mix of highly specific and broader patents, underscoring the importance of careful freedom-to-operate analyses.
7. Conclusions and Recommendations
- U.S. Patent 9,730,890 offers a significant protective barrier for AbbVie’s IL-23 receptor antibody therapies, particularly in treatment of autoimmune diseases.
- The claim scope covers both composition of matter with defined binding properties and methods for treatment, aligning with strategic drug development protections.
- Stakeholders should review the patent's scope against existing patents to assess infringement risks and opportunities for designing around claims.
- Biosimilar developers must consider sequence variances or alternative targets to navigate around the patent landscape legally.
- Continuous monitoring of patent filings and litigation proceedings is crucial to maintaining market positioning.
8. Key Takeaways
- The patent protects a class of high-affinity monoclonal antibodies targeting cytokine receptors, primarily IL-23R, used in autoimmune therapy.
- Claim breadth—covering both composition and therapeutic method—provides strong market exclusivity.
- Understanding the detailed claims and related patents is essential for strategic licensing, R&D, and litigation planning.
- The evolving patent landscape indicates aggressive IP strategies by key players, necessitating ongoing due diligence.
- Future innovations should aim for novel epitopes, unique sequences, or alternative mechanisms to circumvent existing patents.
FAQs
Q1: What is the primary therapeutic application covered by U.S. Patent 9,730,890?
A: It primarily covers therapies involving monoclonal antibodies targeting cytokine receptors like IL-23R for treating autoimmune diseases such as psoriasis and rheumatoid arthritis.
Q2: How broad are the claims in Patent 9,730,890?
A: The claims cover specific high-affinity monoclonal antibodies, their methods of use in treatment, and their pharmaceutical compositions, with some claims directed at particular epitopes and binding affinities.
Q3: What are the key differentiators from prior art?
A: The patent’s novelty lies in specific antibody sequences, high-affinity binding (less than 1 nM), and demonstrated therapeutic methods, which are not disclosed or claimed in prior patents.
Q4: Can competitors develop similar therapies without infringing?
A: Yes, by designing antibodies that target different epitopes, use alternative sequences, or focus on other cytokine receptors, competitors can avoid infringement.
Q5: How does this patent influence global patent strategies?
A: AbbVie’s patent strengthens its global IP portfolio, affecting licensing negotiations, market exclusivity, and potential biosimilar competition in key jurisdictions like Europe, Japan, and China.
References
- U.S. Patent 9,730,890. (2017). Pharmaceutical composition and method for treating autoimmune diseases.
- WIPO Patent Application WO 2014/081801. (2014). Anti-IL-23 antibodies.
- FDA Approvals and Regulatory Filings. (2022).
- Market Reports on Biologic Patent Trends. (2021).
- Legal Analyses of Cytokine Receptor Antibody Patents. (2019).
More… ↓
⤷ Start Trial
|
